My medical partner called me this evening after reading the February 20 issue of the NEJM. The journal had a couple articles about glioblastoma (very highly malignant brain tumor). The issue included a trial of avastin for glioblastoma because of its anti-VEGF properties. It looks like avastin did not improve survival when patients were treated for new tumors.. He asked me "do you think squalamine would work". Interestingly, if you google squalamine and glioblastoma, it looks like Genaera was studying this. I could find some encouraging animal studies. I found some planned human studies but I guess that is when they ran out of money.
Maybe if we get something positive out of the ovarian CA studies, we look at other CA indications....
gs88: squalamine I think needs to be infused at about 100mg for 1 hours weekly for 20 weeks; Genaera's studies dosed it as an 120 hour constant infusion in 3 weekly cycles only, which allowed angiogenesis to start back up again a month after the last dose. But I think the eye drops would work for retinal tumors since they could be used for months and months. This is from Emedicine:
"Retinal tumors can arise from various tissues and cells of origin in the framework between the choroid and the vitreous cavity. For the purpose of a systematic approach, they can be classified in tumors associated with the retinal vasculature (retinal hemangioblastomas and retinal arteriovenous [AV] communications), in tumors arising from retinocytes (retinoblastomas and retinomas), in those arising from retinal glial cells (retinal astrocytic hamartomas and astrocytomas), in tumors arising from lymphatic cells that are present in the retina (primary retinal lymphoma) and in tumors that metastasize to the retina via its blood supply (retinal/vitreoretinal metastases from primary tumors located elsewhere). The wide variety of tumors that are associated with the retinal pigment epithelium (RPE), sum up the systematic classification of retinal tumors. RPE tumors comprise congenital anomalies, such as the simple and combined hamartomas, the congenital hypertrophy of the RPE (that can also be associated with hyperplasia), and true neoplasia of the RPE, such as adenomas and adenocarcinomas. This article also includes tumors that have their primary manifestation early in life but are frequently encountered in a general (adult) ophthalmo–oncological service, such as the syndromal neoplasias or hereditary multi-tumor syndromes, which are commonly, albeit in many cases falsely, named phakomatoses, such as neurofibromatosis (types I and II), the von Hippel–Lindau (VHL) and the Wyburn–Mason syndromes, as well as congenital hypertrophies and hamartomas of the RPE and the retina."